Series A momentum POC Pharma recently closed a $10.3M Series A led by Alven with participation from Picus Capital, FEBE Ventures, and FJ Labs, signaling strong investor confidence and potential for scale, which presents an opportunity to position pharma analytics and data solutions to growing teams during post-funding expansion.

Emerging Markets focus As a data solutions provider aimed at helping pharma stakeholders grow faster and cheaper in Emerging Markets, there is a clear opportunity to upsell regional data services, regulatory intelligence, and cost optimization offerings tailored to emerging market dynamics.

B2B SaaS expansion POC Pharma operates as a B2B service SaaS with a scalable platform, indicating potential for enterprise-level contracts, multi-year subscriptions, and white-label or partner-aligned deployments with pharma distributors, contract research organizations, and regional CROs.

Tech stack leverage Utilize their cloud-first architecture (Google Cloud Platform and Microsoft Azure) and web tech familiarity (PHP, NestJS) to propose integrations with customers’ data systems, analytics workloads, and security requirements like HSTS, emphasizing seamless onboarding and robust data governance.

Growth-ready profile Revenue indicators in the million-dollar range and a strong funding round suggest readiness for strategic partnerships, channel sales, and co-selling opportunities with larger pharma players seeking to accelerate digital transformation in emerging markets.